- Biotech Begins to Demonstrate Strategy to Expand NHL Marketplace with
Novel Antibody and Speedy DXL Screening Preclinical Development Program -
BRITISH COLUMBIA, Canada, Sept. 16 /CNW/ -- InNexus Biotechnology Inc.
(TSX VENTURE: IXS; OTC Bulletin Board: IXSBF; http://www.ixsbio.com), a drug
development company commercializing the next generation of monoclonal
antibodies based on its technology, Dynamic Cross Linking (DXL(TM)), announced
today the results of an extensive mouse tumor study demonstrating superiority
of InNexus' DXL625 (CD20) versus Rituxan(R) in the xenograft model.
InNexus plans to submit the data for publication along with additional
data from animal studies recently completed and presented at the American
Association for Cancer Research (AACR) 2008 Annual Conference. The company
has also launched a large scale study of DXL625 with primates, designed to
evaluate toxicity and pharmokinetics, enabling the company to move the product
to the FDA toward human testing.
"A study performed by an independent group investigating the survival of
mice intravenously injected with B-lymphoma cells and treated subsequently
with DXL625 showed a significant improvement in outcome compared to animals
treated with equivalent doses of Rituxan(R), a commercially available
anti-CD20 antibody," said Dr. Thomas Kindt, InNexus' Chief Scientific Officer.
"Animals treated with either drug had a superior outcome when compared to
those receiving inactive control (vehicle), however DXL625 had a substantial
advantage over the competing antibody. We are confident that these results
will translate to therapeutic advantage when DXL625 is used in human
"The DXL(TM) technology platform builds better antibodies and soon you'll
be able to see our strategy to expand the NHL marketplace. We enhance an
antibody's potency in a real, measurable and predictable fashion," said Jeff
Morhet, Chairman and Chief Executive Officer. "I'm pleased with our
scientific progress, regulatory plans and soon we'll be well positioned to
begin formal discussions with the FDA."
About DXL(TM) Technology Platform
DXL(TM) technology works by integrating self-binding peptides into
monoclonal antibodies, potentiating target binding. Modified antibodies
"cluster" upon engaging the target receptor site, resulting in greater
"molecular mass" at the point of association. DXL(TM) antibodies have
significantly extended dissociation rates, as measured by surface plasmon
resonance. As a consequence, this may facilitate cancer cell destruction in a
target dependent manner by increasing apoptosis, antibody dependent cell
cytotoxicity and complement-dependent cytotoxicity. To learn more about
InNexus' DXL(TM) technology, please visit www.ixsbio.com.
InNexus is a drug development company commercializing the next generation
of monoclonal antibodies based on its DXL(TM) technology, which improves the
potency of new and existing antibody products while opening new markets and
disease applications. DXL(TM) antibodies utilize unique, novel and patented
methods and technologies of InNexus.
InNexus is headquartered in British Columbia with principal management
based in Scottsdale, Arizona on the campus of Mayo Clinic and has its own in-
house developmental facilities. These development resources provide validation
of protein and peptide discoveries, enabling InNexus (and its strategic
partners) to advance novel drug therapeutics and diagnostics. To learn more
about InNexus, please visit http://www.ixsbio.com.
The TSX Venture Exchange has not reviewed and does not accept
responsibility for the adequacy or accuracy of this news release. This news
release may contain assumptions, estimates, and other forward-looking
statements that involve inherent risks and uncertainties and are subject to
factors, many of which are beyond the Company's control that may cause actual
results or performance to differ materially from those currently anticipated
in such statements.
For further information:
For further information: Jeff Morhet, Chairman & Chief Executive
Officer, +1-480-862-7500, or Dr. Thomas Kindt, Chief Scientific Officer,
+1-480-862-7500, both of InNexus Biotechnology Inc. Web Site: